We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

76 hedge funds and large institutions have $104M invested in Carisma Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

209% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 11

179% more capital invested

Capital invested by funds: $37.3M → $104M (+$67M)

36% more funds holding

Funds holding: 56 → 76 (+20)

0.12% more ownership

Funds ownership: 1.07% → 1.18% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

19% less call options, than puts

Call options by funds: $2.58M | Put options by funds: $3.2M

Holders
76
Holders Change
+20
Holders Change %
+35.71%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
25
Increased
34
Reduced
11
Closed
5
Calls
$2.58M
Puts
$3.2M
Net Calls
-$619K
Net Calls Change
-$525K

Top Buyers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
+$7.09M
2
Two Sigma Investments
Two Sigma Investments
New York
+$6.19M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$5.33M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07M
5
BlackRock
BlackRock
New York
+$2.4M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$4.1M
2
EP
Eversept Partners
New York
-$2.11M
3
TG
TRV GP
Massachusetts
-$1.77M
4
KCM
Kingdon Capital Management
New York
-$944K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$411K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
26
Acadian Asset Management
Massachusetts
$396K +$358K +7,595 New
Barclays
27
Barclays
United Kingdom
$392K +$355K +7,532 New
Goldman Sachs
28
Goldman Sachs
New York
$382K +$267K +5,653 +333%
Simplex Trading
29
Simplex Trading
Illinois
$360K +$214K +4,539 +190%
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$325K +$295K +6,255 New
State Street
31
State Street
Massachusetts
$305K +$16K +340 +6%
Vontobel Holding
32
Vontobel Holding
Switzerland
$273K +$248K +5,250 New
LP
33
LMR Partners
United Kingdom
$263K +$212K +4,490 +802%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$237K -$98.6K -2,090 -31%
HT
35
HAP Trading
New York
$211K +$192K +4,062 New
AWS
36
AJ Wealth Strategies
New York
$206K – – –
First Manhattan
37
First Manhattan
New York
$161K +$146K +3,100 New
SFI
38
Susquehanna Fundamental Investments
Pennsylvania
$149K +$135K +2,870 New
Charles Schwab
39
Charles Schwab
California
$147K – – –
Ameriprise
40
Ameriprise
Minnesota
$129K +$79K +1,674 +208%
Capstone Investment Advisors
41
Capstone Investment Advisors
New York
$117K -$115K -2,433 -52%
Balyasny Asset Management
42
Balyasny Asset Management
Illinois
$114K +$103K +2,185 New
Squarepoint
43
Squarepoint
New York
$110K +$99.5K +2,108 New
RJA
44
Raymond James & Associates
Florida
$97K +$88.2K +1,870 New
Cambridge Investment Research Advisors
45
Cambridge Investment Research Advisors
Iowa
$93K +$25.8K +547 +44%
TRCT
46
Tower Research Capital (TRC)
New York
$78K +$42.6K +903 +153%
CG
47
Cutler Group
California
$65K +$30.2K +640 +103%
Victory Capital Management
48
Victory Capital Management
Texas
$63K +$9.44K +200 +20%
Mercer Global Advisors
49
Mercer Global Advisors
Colorado
$61K +$23.3K +494 +73%
JG
50
Jefferies Group
New York
$56.7K +$51.4K +1,090 New
1
2
3 4

CARM Hedge Fund Activity: Q1 2021 in Review

76 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2021, worth a combined $104M — up 179% from $37.3M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CARM positions and 5 closed out — a net gain of 20 holders — while 34 added to existing stakes and 11 trimmed.

The largest buyer was Schonfeld Strategic Advisors, adding an estimated $7.09M. The largest seller was Morgan Stanley, cutting an estimated $4.1M.

  • 76 institutional investors held Carisma Therapeutics (CARM) as of Q1 2021, up from 56 in Q4 2020.
  • Funds reported $104M of Carisma Therapeutics stock for Q1 2021, up 179% quarter-over-quarter.
  • 25 funds opened new Carisma Therapeutics positions in Q1 2021 and 5 closed out, a net change of +20 holders.
  • The largest Carisma Therapeutics buyer in Q1 2021 was Schonfeld Strategic Advisors, an estimated $7.09M added.
  • The largest Carisma Therapeutics seller in Q1 2021 was Morgan Stanley, an estimated $4.1M sold.

Based on aggregated 13F filings for Q1 2021.